Affiliated Companies

SPIMACO was established in the year 1986 in the Kingdom of Saudi Arabia (as a Public Joint Stock Company). SPIMACO and its subsidiaries are engaged in medical and pharmaceutical production including manufacturing, producing, developing, marketing, selling and distributing pharmaceutical raw materials, medical and pharmaceutical solutions, production supplies, medical and pharmaceutical supplies and equipment in addition to producing medical consumables in addition to other investment in many companies.SPIMACO capital amounts to SAR 1.2 billion, of which ACDIMA owns 20.488%.

JULPHAR was established in the year 1980 in the United Arab Emirates, as a public joint stock company, it is currently one of the largest pharmaceutical manufacturers in the Middle East and North Africa, distributing medicine in more than 40 Countries. The company has factories in the United Arab Emirates specialized in producing pills, solutions and suspensions. The company also established several factories in Ethiopia, Bangladesh and Saudi Arabia as part of its continuous global expansion strategy. JULPHAR's capital amounts to AED 1.159 billion, of which ACDIMA owns 9.1509%.

ACDIMA Center for Bioequivalence and Pharmaceutical Studies was established in the year 2000, to conduct bioavailability, bioequivalence, clinical, pharmacokinetics and pharmaceutical studies for a number of pharmaceutical companies in the Arab and Foreign Countries. The BioCenter is now accredited by a large number of Arab and International Health Authorities, as it attained the accreditation of the World Health Organization “WHO”  From its side, ACDIMA provided continuous support for this project through training and qualifying technical personnel and providing modern equipment and supplies to the Center.ِof which ACDIMA owns 100%

ACAI was established in 1975 as an Arab joint stock company. ACAI opened its factory in 1997 and produces antibiotic in its diffrent  forms according to the latest specifications of good pharmaceutical manufacturing. ACAI products have earned a good reputation in Iraq and its products have been registered in a number of Arab countries. The company is following the developments in the antibiotic industry and working on the manufacture of new varieties, in line with the global production and in order to qualify for the entry of international markets in the future. The company’s capital is nearly Iraqi Dinars 87.5 billion, of which ACDIMA owns 34.06%.

SAIPH was established in the year 1992 through joint Arab financing and is considered as one of the pioneering companies in Tunisia. It includes five factories for the production .SAIPH distributes its products in Tunisia and to several Arab and African Countries. It also  produces medicine with generic licenses and genetic medicine, and has developed the concept of handling for some local and international laboratories. SAIPH capital nearly amounted to TND 62 million, of which ACDIMA owns 83.495%. 

CAD was established in the year 2006 in Saudi Arabia and is considered a modern and multi-objective industrial enterprise, designed on the concept of separate manufacturing units, while deploying advanced technical systems for manufacturing high quality Active Pharmaceutical Ingredients (APIs) in consistence. The products of CAD are marketed in the Arab Countries and abroad CAD capital is SAR 266 million, of which ACDIMA owns 25%.

Arab Company for Drugs was established in the year 2007 by an Arab investment, and is considered the largest company in Sudan in the production of human and veterinary medicines. AD was designed and structured following the highest standards, so that it is compatible with international laws and regulations set in the field of manufacturing medicine.The company's factory is designed with three different production lines equipped with state-of-the-art equipment.  cover Sudan and neighboring countries.  AD capital amounts to USD 44 million, of which ACDIMA owns 40%.  

ARABIO was established in the year 2005 in saudi arabi  and is considered a leading company in manufacturing and marketing vaccines and biological products, in addition to conducting research.The company's factory began its production activities in 2011 with the production of a number of vaccines with support, cooperation and strategic partnerships with a number of international companies specialized in vaccines manufacturing. The factory was equipped with the latest machines to meet local and global requirements.ARABIO's capital amounted to SAR 186 million, of which ACDIMA owns 31.38%.

TAPHCO was established in the year 2000 in Algeria , commencing commercial production in 2017 of selected drugs covering various therapeutic segments under TAPHCO trademarks. The company also does contracted productions for SPIMACO to manufacture and produce some of SPIMACO’s agreed upon drugs. TAPHCO also purchased production files from distinguished international pharmaceutical companies, while enjoying high revenues in the Algerian Market. The company’s capital is nearly DZD 1.083 billion, of which ACDIMA owns 28.98%.

A joint stock company established in 2000 under the name of ePharma. The company started its production and marketing activities at its factory in Tangier since 2003. The company’s main purposes are manufacturing, converting, importing and exporting as well as distribution and wholesale in the internal and external market for all pharmaceutical products, cosmetics, and personal hygiene products in addition to any other products for human or veterinary medicine.The company’s capital is nearly MAD 567 billion, of which ACDIMA owns 20.01%.

This company was established in the year 2018 in the Ivory Coast, with the aim of building a factory for the production of pharmaceuticals and cosmetics, and all essential and additional vital products, buying, selling, supplying and exporting these products in addition to medical promotion of related materials. SAPIH Ivoire’s capital amounts to CFA 1 million, of which ACDIMA owns 10%

ACDIMA owns 43.9% in the capital of Shamra Pharma, which amounts to SYP 144 million. Company production was suspended since June, 2012, due to the prevailing circumstances in Syria. ACDIMA’s Board of Directors took a resolution to allocate an “investment impairment provision” for the whole investment value of this company, in accordance with the generally accepted accounting standards

APICO is still being established, while aiming at setting up a factory for intravenous solutions in addition to producing and marketing all kinds of intravenous solutions. APICO's vision is in concordance with the strategy, objectives and goals of ACDIMA represented in supporting the pharmaceutical industry in the Arab World while concentrating on diversification and covering all therapeutic categories and segments. APICO's capital is LYD 1 million, of which ACDIMA owns 49%.

ACDIMA for Veterinary Medicines Industry “ACDIVET” was established in the year 1999, to support the mother company “ACDIMA” in the Veterinary Medicine Industry, as it employs its intensive experience in the human medicine industry accumulated from its various contributions in many human medicine and solution manufacturing companies. ACDIVET manufactures most of the veterinary solutions in different therapeutic forms and pharmaceutical formulas in accordance with the highest international standards.ACDIVET capital amounts to SYP 210 million, of which ACDIMA owns 100%.